Eximo Medical Ltd. announced it has received 510(k) clearance from the U. S. Food & Drug Administration (FDA) for its B-Laser Atherectomy System for Peripheral Artery Disease (PAD). B-Laser is a transformative 355nm wavelength laser technology designed to address unmet clinical needs for treating multiple vascular indications. The specific indication cleared by the FDA is: “The B-Laser Atherectomy System is intended for use in the treatment, including atherectomy, of infrainguinal stenoses and occlusion, including in-stent restenosis (ISR).”
 
“This clearance represents a significant milestone for Eximo, as we can now offer the B-Laser Atherectomy System for PAD in the US. This is the first 355nm laser system cleared in the U.S. for this purpose and, according to the clinical results and the feedback that we received from physicians, it seems that this wavelength provides significant advantages over traditional 308nm excimer lasers in term of safety, efficacy, cost, and ease of use,” said Yoel Zabar, CEO of Eximo Medical. “We also plan to leverage our B-Laser platform technology to develop additional devices to address significant unmet needs in other vascular indications, including lead extraction (for which we have completed a proof of concept), CAD, Thrombectomy and Venous Disease. Additionally, we are developing an add-on diagnostic tool and disruptive medical device for interventional gastrointestinal procedures.”
 
Clinical evaluation of the B-Laser device in the intended population was performed in a prospective, single-arm, multi-center, open-label, non-randomized pilot clinical study in 50 subjects in Europe, as well as in a pivotal, prospective, single-arm, multi-center, open-label, non-randomized IDE clinical study in 97 subjects in U.S. and Europe.
 
In the pilot clinical study, the results presented 100 percent success in crossing the target with no device-related perioperative clinically significant adverse events and no complications requiring intervention. There were no major adverse events (MAE) at one month and six months post-procedure, and only two cases (4.3%) of TLRs among 46 subjects who completed the 1-year post-procedure follow-up. In the pivotal study, the safety and efficacy primary endpoints were achieved with high margins and the 6-months data was consistent with the pilot study results.
 
“I used the B-Laser in challenging procedures during the pivotal study and found the device easy to set up and use, and a valuable addition to our treatment portfolio,” said the national PI, Dr. John Rundback, Interventional Radiologist and Director of the Interventional Institute at Holy Name Medical Center, Teaneck, N.J. “The enrollment in both US and Europe was quick (6.5 months), and the study results up to six months have been very impressive despite treating diverse lesions such as calcium, thrombus, and restenosis including ISR, both above and below the knee."
 
“I have been working with the company for a long time, and I am happy to see that the technology matured to provide a competitive edge over existing solutions. I look forward to seeing additional indications for the benefit of other patients as well,” said SAB member, Dr. Kenneth Rosenfield, Section Head for Vascular Medicine and Intervention at Massachusetts General Hospital.
 
“I have been extremely impressed with the results with the B-Laser Atherectomy System demonstrated in the clinical trials. The excellent safety profile combined with extremely low need for repeat procedures make this a very promising alternative for our patients with complex vascular disease,” said SAB member Dr. John Laird, Medical Director of the Adventist Heart and Vascular Institute.